Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Product Surveillance, Postmarketing | 2 | 2013 | 36 | 0.760 |
Why?
|
| Medical Records | 2 | 2013 | 121 | 0.720 |
Why?
|
| Rotavirus Vaccines | 2 | 2013 | 8 | 0.480 |
Why?
|
| Consumer Product Safety | 1 | 2013 | 11 | 0.380 |
Why?
|
| Uncertainty | 1 | 2013 | 78 | 0.370 |
Why?
|
| Patient Safety | 1 | 2013 | 219 | 0.320 |
Why?
|
| Models, Statistical | 1 | 2013 | 584 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 916 | 0.280 |
Why?
|
| Vaccines, Attenuated | 2 | 2013 | 52 | 0.190 |
Why?
|
| Acute Kidney Injury | 2 | 2015 | 339 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 1071 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 215 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 96 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 154 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 57 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 37 | 0.100 |
Why?
|
| Cisplatin | 1 | 2016 | 567 | 0.100 |
Why?
|
| Food Contamination | 1 | 2013 | 35 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 504 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 706 | 0.100 |
Why?
|
| Oryza | 1 | 2013 | 44 | 0.100 |
Why?
|
| Intussusception | 1 | 2013 | 10 | 0.100 |
Why?
|
| Normal Distribution | 1 | 2013 | 38 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 381 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 244 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 327 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 159 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 383 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2013 | 355 | 0.080 |
Why?
|
| Arsenic | 1 | 2013 | 272 | 0.080 |
Why?
|
| Carcinoma | 1 | 2013 | 439 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 441 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2485 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 940 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 1073 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3450 | 0.060 |
Why?
|
| Graft vs Host Reaction | 1 | 2006 | 14 | 0.060 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2006 | 66 | 0.060 |
Why?
|
| Infant | 1 | 2013 | 3156 | 0.060 |
Why?
|
| RNA Editing | 1 | 2006 | 46 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2301 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2006 | 276 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 3155 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 116 | 0.050 |
Why?
|
| Humans | 9 | 2018 | 93138 | 0.050 |
Why?
|
| Middle Aged | 7 | 2018 | 27539 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 2009 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1171 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 27850 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 9074 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 3044 | 0.030 |
Why?
|
| Female | 6 | 2018 | 48547 | 0.030 |
Why?
|
| Aged | 4 | 2016 | 20398 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 45 | 0.030 |
Why?
|
| Male | 5 | 2016 | 44360 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1172 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 494 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 293 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 161 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2014 | 336 | 0.020 |
Why?
|
| Dermatitis | 1 | 2013 | 33 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 148 | 0.020 |
Why?
|
| Weight Loss | 1 | 2015 | 234 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5901 | 0.020 |
Why?
|
| Drinking Water | 1 | 2013 | 70 | 0.020 |
Why?
|
| Bangladesh | 1 | 2013 | 340 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1518 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 446 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2013 | 173 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 709 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 505 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 319 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 875 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 985 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 372 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 10132 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1160 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4546 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1318 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2465 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1697 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1452 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1910 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1447 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4265 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3815 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3891 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 7039 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 5380 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 941 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1581 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 6922 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 9550 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 3431 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 12230 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 27973 | 0.000 |
Why?
|